摘要
目的观察吡柔比星(THP)联合阿糖胞苷(Ara-C)治疗急性髓细胞白血病(AML)的临床疗效和毒副反应。方法 20例AML患者(含初治者8例,复发者2例,巩固强化者10例),化疗方案采用TA治疗。结果 2例复发者均为一疗程获完全缓解(CR);8例初治者2例获CR,其中1例为二疗程获CR,1例化疗结束后因颅内出血死亡;10例巩固强化者外周血三系列造血细胞均有不同程度的下降。毒副反应示85%有骨髓抑制,55%～95%有消化道反应,但患者均能耐受。结论 TA方案治疗AML疗效肯定,副反应轻微。
Objective To analyze the clinical therapeutic effects and side effects of pirarubicin（THP） com- bined with Ara-C for acute myelogeneous leukemia（AML）. Methods Twenty patients with AML（8 untreated,2 relapsed,and 10 postremission）were treated by THP combined with Ara-C. Results All of 2 patients with relapsed AML achieved complete remission（CR） after one course of chemotherapy and among 8 untreated patients with AML, 2 achieved CR and 1 died after one course of chemotherapy. Ten patients with postremission showed different degree of decrease in WBC,Hb and pletelet counting. The marrow suppression and digestive side effect of TA regimen were observed in 85% and 55% to 95% of AML patients separately. Conclusion TA chemotherapy regimen for AML has definitive effects and slight side effects.
出处
《中国临床新医学》
2010年第12期1230-1231,共2页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词
急性髓细胞白血病
TA化疗方案
疗效
Acute myelogeneous leukemia
TA chemotherapy regimen
Therapeutic effects
